Phase 2 Hypertension Trial, Recruiting NCT06826859 Sponsor: Thomas Jefferson University Condition: Hypertension
Back to Hypertension

Phase 2 Hypertension Trial, Recruiting

NCT06826859
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are pregnant with a single baby and are less than 16 weeks along, with the pregnancy dates confirmed by ultrasound
  • People who have at least one high-risk factor for preeclampsia (a serious condition involving high blood pressure in pregnancy), or at least two moderate risk factors, as defined by United States health guidelines from 2021
  • People for whom a doctor has recommended taking 162mg of aspirin daily during pregnancy
  • People who are between 16 and 55 years old

Who may not be able to join:

  • People who have a medical reason why they cannot take aspirin
  • People who are currently using or planning to use any blood-thinning medication other than aspirin
  • People who have a low platelet count, or any known condition affecting platelets or blood clotting
  • People who had an abnormal result on a specific blood clotting test (called a PFA-100 epinephrine closure time test) before starting aspirin (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 215-955-5000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Thomas Jefferson University
Registry
ClinicalTrials.gov
Start date
26 June 2025
Est. completion
1 July 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Aspirin Response PFA-100 epinephrine closure time (seconds)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov